Corvus Pharmaceuticals, Inc. (CRVS)
| Market Cap | 992.63M +120.5% |
| Revenue (ttm) | n/a |
| Net Income | -54.13M |
| EPS | -0.62 |
| Shares Out | 84.12M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,143,025 |
| Open | 12.46 |
| Previous Close | 12.54 |
| Day's Range | 11.51 - 12.48 |
| 52-Week Range | 6.12 - 26.95 |
| Beta | 0.86 |
| Analysts | Strong Buy |
| Price Target | 33.14 (+180.85%) |
| Est. Earnings | Nov 3, 2026 |
About CRVS
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company’s lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1b/2 clinical trial for the treatment of peripheral T cell lymphoma, atopic dermatitis, hidradenitis suppurativa, autoimmune lymphoproliferat... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for CRVS stock is "Strong Buy." The 12-month stock price target is $33.14, which is an increase of 180.85% from the latest price.
News
Corvus Pharmaceuticals Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Soquelitinib, an oral ITK inhibitor, is advancing through phase III for PTCL and phase II for atopic dermatitis, with strong safety and efficacy data supporting expansion into asthma and HS. Key clinical and biomarker data, along with major trial readouts, are expected from late 2024 through 2028.
Corvus Pharmaceuticals to Present at the 2026 Cantor Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership ...
Corvus Pharmaceuticals Announces Publication in Blood of Final Phase 1 Data from the Soquelitinib Phase 1/1b T Cell Lymphoma Trial
Data supports ongoing registration Phase 3 trial in r/r PTCL, Phase 2 trial in atopic dermatitis and planned trials for hidradenitis suppurativa and asthma Data in T cell lymphoma demonstrated anti-t...
Corvus Pharmaceuticals Earnings Call Transcript: Q2 2026
R&D expenses and net loss more than doubled year-over-year, with a strong cash position supporting operations into 2028. Clinical progress for soquelitinib continues across multiple indications, with key data readouts and trial initiations expected through 2027.
Corvus Pharmaceuticals Earnings release: Q2 2026
Corvus Pharmaceuticals released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Corvus Pharmaceuticals Quarterly report: Q2 2026
Corvus Pharmaceuticals has published its Q2 2026 quarterly earnings report on August 6, 2026.
Corvus Pharmaceuticals reports Q2 EPS (19c), consensus (17c)
“We believe soquelitinib, our oral, selective ITK inhibitor, is well positioned as a potential new treatment paradigm for patients across a broad range of diseases, based on a novel mechanism…
Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2026 Financial Results
Enrollment in soquelitinib registrational Phase 3 relapsed/refractory peripheral T-cell lymphoma (PTCL) and Phase 2 atopic dermatitis trials on track Soquelitinib's potential in atopic dermatitis and ...
Corvus Pharmaceuticals Slides: Corporate presentation
Corvus Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on August 6, 2026.
Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2026 Financial Results on August 6, 2026
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT
Corvus Pharmaceuticals Announces Additional Investment in Angel Pharmaceuticals to Advance the Development of Soquelitinib in China
$13.5 million financing, including $5 million from Corvus, supports ongoing generation of soquelitinib clinical data in China for atopic dermatitis and asthma, which are indications also in developmen...
Corvus Pharmaceuticals Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Soquelitinib is advancing in phase III for PTCL and phase II for AD, with additional studies in asthma and HS planned. The drug's unique ITK inhibition and oral formulation offer differentiation, and strong IP plus orphan status provide exclusivity. Cash reserves support operations into mid-2028.
Corvus Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026
Soquelitinib, a selective ITK inhibitor, shows promising efficacy and durability in atopic dermatitis and lymphoma, with a clean safety profile and broad potential across immune diseases. Ongoing and planned trials aim to expand indications and support global regulatory filings.
Corvus Pharmaceuticals Slides: FY 2026
Corvus Pharmaceuticals has posted slides in relation to its FY 2026 quarterly earnings report, which was published on June 3, 2026.
Corvus Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership te...
Corvus Pharmaceuticals Transcript: Study update
Soquelitinib demonstrated rapid, deep, and durable clinical responses in moderate to severe atopic dermatitis, with a clean safety profile and no rebound after treatment. Mechanistic data show selective immune modulation and increased Tregs, supporting potential disease modification and broad applicability.
Corvus Pharmaceuticals Press release: Study update
Corvus Pharmaceuticals issued a press release on May 14, 2026, disclosing material business information to investors.
Corvus Pharmaceuticals Slides: Study update
Corvus Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on May 14, 2026.
Corvus Pharmaceuticals Presents Soquelitinib Phase 1 Atopic Dermatitis Data at the Society for Investigative Dermatology (SID) Annual Meeting
New immunologic and biomarker data supports the potential of ITK inhibition with soquelitinib to increase persistent Treg cells and influence multiple inflammatory pathways. Data supports potential fo...
Corvus Pharmaceuticals reports Q1 EPS (15c), consensus (15c)
“We started the year with strong momentum for soquelitinib, our selective ITK inhibitor that we believe is well positioned to improve therapy for a broad range of patients with atopic…
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2026 Financial Results
Soquelitinib clinical development for atopic dermatitis advancing with Phase 1 cohort 4 positive data and initiation of Phase 2 trial during the quarter New immunologic and biomarker data supporting t...
Corvus Pharmaceuticals Earnings release: Q1 2026
Corvus Pharmaceuticals released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Corvus Pharmaceuticals Quarterly report: Q1 2026
Corvus Pharmaceuticals has published its Q1 2026 quarterly earnings report on May 7, 2026.
Corvus Pharmaceuticals Proxy statement: Proxy filing
Corvus Pharmaceuticals filed a proxy statement on April 24, 2026, providing details for shareholder voting and corporate governance matters.
Corvus Pharmaceuticals Proxy statement: Proxy filing
Corvus Pharmaceuticals filed a proxy statement on April 24, 2026, providing details for shareholder voting and corporate governance matters.